$ANIX

$2.93 -$0.06 (2.01%) Close

$ANIX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 34.8M shares outstanding

Who owns ANIX?

By type of holder

Institutions 15.4% Insiders 5.5% Everyone else 79.1%

Concentration Top 10 holders own 39.2%

Amit Kumar 17.8% · Michael Catelani 7.1%

Institutional ownership

15.4%

+0.7 pts vs last qtr

Institutional holders

+3 vs last qtr

Net shares bought

+252.5K

by institutions in Q2 2026

New / sold out

10 / 7

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Marshall Wace, LLP +155.2K
UBS Group AG +33.8K

Biggest sellers in Q2 2026

Susquehanna International Group, LLP SOLD OUT −99.5K
Point72 Asset Management, L.P. SOLD OUT −17.3K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Anixa Biosciences Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

−99.9%

−81.64% a year

Each share's claim on the business

+87960.0%

grew without buying or selling a share

Spent on buybacks vs paid in stock

$6K vs $26M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years56% 3–5 years5% 1–3 years35% Under 1 year4%

Quarterly turnover

6.3%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting ANIX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
VC Vanguard Capital Management LLC	1.3M	3.83%	+14.9K (+1.1%)	≤2021	0.0%
Shares held by quarter Peak holding1.3M (Q2'26) Change over 8 quarters+1.3M Share of the company3.830% Vanguard Capital Management LLC's full portfolio →
UG UBS Group AG	585.4K	1.68%	+33.8K (+6.1%)	≤2021	0.0%
Shares held by quarter Peak holding585.4K (Q2'26) Change over 8 quarters+56.0K Share of the company1.680% UBS Group AG's full portfolio →

Vanguard Capital Management LLC

1.3M

% of company

3.83%

Change vs last qtr

+14.9K (+1.1%)

Held since

≤2021

UBS Group AG

585.4K

% of company

1.68%

Change vs last qtr

+33.8K (+6.1%)

Held since

≤2021

28 more super investors behind a free account

See every manager holding Anixa Biosciences Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ANIX on Form N-PORT; together they hold 5.0% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$2.62M	936.9K	2.70%	0.00%	June 30, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$991K	353.9K	1.02%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$2.62M

% of company

2.70%

% of the fund

0.00%

As of

June 30, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$991K

% of company

1.02%

% of the fund

0.00%

As of

June 30, 2026

11 more funds behind a free account

See every fund holding Anixa Biosciences Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
AK Amit Kumar 5%+ holder 13D · 16.3%	6.2M	17.76%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company17.760% Disclosed stake13D · 16.3% View the 13D/G filing →
MC Michael Catelani 5%+ holder 13D · 7.0%	2.5M	7.10%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company7.100% Disclosed stake13D · 7.0% View the 13D/G filing →

Amit Kumar

5%+ holder13D · 16.3%

6.2M

% of company

17.76%

Change vs last qtr

—

Held since

—

Michael Catelani

5%+ holder13D · 7.0%

2.5M

% of company

7.10%

Change vs last qtr

—

Held since

—

2 more holders behind a free account

See every insider and 5%+ holder of Anixa Biosciences Inc.

Comments